Demand for remdesivir continues to outstrip supply in many parts of the world.
Gilead’s chief executive, Daniel O’Day, on a conference call, said the company expects by the end of September to be producing enough remdesivir to meet real-time global demand.
Gilead said it still expects to manufacturer 2 million or more remdesivir treatment courses cumulatively in 2020, and its revenue outlook reflects expected sales of up to 1.5 million courses this year.
Data on children as sources of coronavirus spread are sparse, and early reports did not find strong evidence of children as major contributors to the deadly virus that has killed 669,632 people globally.
Understanding the transmission potential in children will be key to developing public health guidelines, said the researchers who published the study in the journal JAMA Pediatrics.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.